CD274 and non-small cell lung carcinoma: (vi) Cemiplimab: Cemiplimab, a monoclonal IgG4 antibody targeting PD-L1 approved to treat metastatic cutaneous squamous cell carcinoma.55 The effectiveness of cemiplimab monotherapy and platinum-derived chemotherapy as a primary treatment for late-stage NSCLC expressing PD-L1 was compared in the EMPOWER-Lung 1 (NCT03088540) phase III trial.